Aug 04, 2020 / 08:30PM GMT
Operator
Welcome to Acorda Therapeutics' Second Quarter 2020 Financial and Business Update. (Operator Instructions). Please be advised that this call is being taped at the company's request. I would now introduce your host for today's call, Tierney Saccavino, Executive Vice President, Corporate Communications at Acorda. Please go ahead.
Tierney Saccavino - Acorda Therapeutics, Inc. - EVP of Corporate Communications
Thank you. Good afternoon, everyone. Before we begin, let me remind you that our presentation will contain forward-looking statements. Detailed disclosures can be found in our SEC filings, which are public and which we encourage you to refer to. I will now pass the call over to our CEO, Ron Cohen. Ron?
Ron Cohen - Acorda Therapeutics, Inc. - Founder, CEO, President & Director
Thanks, Tierney. Good afternoon, everyone. Starting with AMPYRA. AMPYRA net revenue for the second quarter was $26.1 million. And these, as well as July sales, were consistent with our internal projections. Physicians and patients are
Q2 2020 Acorda Therapeutics Inc Earnings Call Transcript
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot